We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+11.1%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$440M
AUM Growth
+$9.07M
Cap. Flow
-$6.96M
Cap. Flow %
-1.58%
Top 10 Hldgs %
52.42%
Holding
87
New
10
Increased
20
Reduced
29
Closed
4

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$10.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$5.13M
3
LRMR icon
Larimar Therapeutics
LRMR
+$4.36M
4
BCAX
Bicara Therapeutics
BCAX
+$2.76M
5
FULC icon
Fulcrum Therapeutics
FULC
+$1.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$9.76M
2
AXGN icon
Axogen
AXGN
+$7.38M
3
ATXS
Astria Therapeutics
ATXS
+$3.99M
4
RVMD icon
Revolution Medicines
RVMD
+$2.41M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.01%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, DAFNA Capital Management held 87 positions worth $440M, up 2.1% from $431M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2026 filing shows 10 new, 20 increased, 29 reduced and 4 closed positions. Its largest new stake was Fulcrum Therapeutics: 205,000 shares worth $1.57M. The largest sale was Cytokinetics, an estimated $9.76M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier.

  • DAFNA Capital Management's largest Q1 2026 buy was Fulcrum Therapeutics: 205,000 shares worth $1.57M.
  • DAFNA Capital Management added most to Compass Pathways in Q1 2026, an estimated $10.8M increase.
  • DAFNA Capital Management's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $9.76M.
  • DAFNA Capital Management fully exited Astria Therapeutics in Q1 2026, selling an estimated $3.99M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $440M portfolio in Q1 2026.
  • DAFNA Capital Management opened 10 new positions and closed 4 in Q1 2026.
  • DAFNA Capital Management's portfolio value rose 2.1% quarter-over-quarter to $440M.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.